Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.

Pigment cell & melanoma research - 1 Mar 2014

Choi Jaehyuk, Landrette Sean F, Wang Tiffany, Evans Perry, Bacchiocchi Antonella, Bjornson Robert, Cheng Elaine, Stiegler Amy L, Gathiaka Symon, Acevedo Orlando, Boggon Titus J, Krauthammer Michael, Halaban Ruth, Xu Tian

Abstract excerpt

BRAF inhibitors improve melanoma patient survival, but resistance invariably develops. Here we report the discovery of a novel BRAF mutation that confers resistance to PLX4032 employing whole-exome sequencing of drug-resistant BRAF(V600K) melanoma cells. We further describe a new screening approach, a genome-wide piggyBac mutagenesis screen that revealed clinically relevant aberrations (N-terminal BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Transposable Elements
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Mutagenesis, Insertional

Share to Mutant Proteins

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24283590
DOI: 10.1111/pcmr.12197
PMCID: PMC4065135

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.PMID 24283590Read ↗

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.Semantic proximity Read ↗

MEK1 mutations confer resistance to MEK and B-RAF inhibitionSemantic proximity Read ↗

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation eventsSemantic proximity Read ↗

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.Semantic proximity Read ↗

Targeting BRAF in advanced melanoma: a first step toward manageable disease.Semantic proximity Read ↗

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.